Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite Allergy Trial In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 5-11 years~* A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening~* Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period~* Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period~* Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening~* Lung function ≥ 70% of predicted value~Exclusion Criteria:~* Sensitised and regularly exposed to perennial allergens~* Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation~* Asthma requiring treatment with high dose of inhaled corticosteroid~* A relevant history of systemic allergic reaction

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): HDM SLIT-tablet plus allergy and asthma rescue medication
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablet plus allergy and asthma rescue medication

Based on this trial design, predict the completion outcome and termination type (if applicable).